GSK fights compensation claims from UK patients who took rosiglitazoneBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f695 (Published 01 February 2013) Cite this as: BMJ 2013;346:f695
- Clare Dyer
GlaxoSmithKline, the UK based multinational that makes the antidiabetes drug rosiglitazone (marketed as Avandia), is fighting compensation claims from UK patients who allege that the drug harmed them, even though the company has already paid billions of dollars to settle tens of thousands of similar claims in the United States.
Rosiglitazone, and the drug in combination with metformin (Avandamet), were withdrawn from the market in Europe in 2010 after studies showed that it could raise the risk of heart attack.1 When it was taken off the European market it is thought that around 90 000 patients in the United Kingdom …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial